BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 15574789)

  • 21. Kruppel-like factor 6 in the progression and prognosis of malignant melanoma.
    Cai D; Zhao J; Sun Q
    J Int Med Res; 2014 Feb; 42(1):184-90. PubMed ID: 24366496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stage-specific prognostic biomarkers in melanoma.
    Cheng Y; Lu J; Chen G; Ardekani GS; Rotte A; Martinka M; Xu X; McElwee KJ; Zhang G; Zhou Y
    Oncotarget; 2015 Feb; 6(6):4180-9. PubMed ID: 25784655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleolin protein expression in cutaneous melanocytic lesions.
    Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
    J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of adenylate cyclase-associated protein 2 is a novel prognostic marker in malignant melanoma.
    Masugi Y; Tanese K; Emoto K; Yamazaki K; Effendi K; Funakoshi T; Mori M; Sakamoto M
    Pathol Int; 2015 Dec; 65(12):627-34. PubMed ID: 26374196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
    Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
    Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
    Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
    Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maspin expression in the invasive margin of primary melanomas may reflect an aggressive tumor phenotype.
    Pföhler C; Knöpflen T; Körner R; Vogt T; Rösch A; Müller CS
    J Dtsch Dermatol Ges; 2013 Oct; 11(10):993-9. PubMed ID: 23848940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction.
    Berger AJ; Davis DW; Tellez C; Prieto VG; Gershenwald JE; Johnson MM; Rimm DL; Bar-Eli M
    Cancer Res; 2005 Dec; 65(23):11185-92. PubMed ID: 16322269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
    Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD
    Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Significance of Nuclear Phospho-ATM Expression in Melanoma.
    Bhandaru M; Martinka M; McElwee KJ; Rotte A
    PLoS One; 2015; 10(8):e0134678. PubMed ID: 26275218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased expression of Apaf-1 with progression of melanoma.
    Mustika R; Budiyanto A; Nishigori C; Ichihashi M; Ueda M
    Pigment Cell Res; 2005 Feb; 18(1):59-62. PubMed ID: 15649154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
    Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B
    Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance.
    Nambiar S; Mirmohammadsadegh A; Hassan M; Mota R; Marini A; Alaoui A; Tannapfel A; Hegemann JH; Hengge UR
    Carcinogenesis; 2007 Dec; 28(12):2501-10. PubMed ID: 17768177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
    de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
    Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative histopathology of grey-horse-melanoma and human malignant melanoma.
    Seltenhammer MH; Heere-Ress E; Brandt S; Druml T; Jansen B; Pehamberger H; Niebauer GW
    Pigment Cell Res; 2004 Dec; 17(6):674-81. PubMed ID: 15541026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
    Špirić Z; Eri Ž; Erić M
    Int J Surg Pathol; 2015 Dec; 23(8):629-37. PubMed ID: 25911567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
    Wang Y; Dai DL; Martinka M; Li G
    Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma.
    Mihic-Probst D; Kuster A; Kilgus S; Bode-Lesniewska B; Ingold-Heppner B; Leung C; Storz M; Seifert B; Marino S; Schraml P; Dummer R; Moch H
    Int J Cancer; 2007 Oct; 121(8):1764-70. PubMed ID: 17597110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.